Latham & Watkins Advises the Underwriters in Amwell’s Upsized Initial Public Offering

A New York-based capital markets team advised the underwriters in the telehealth company’s offering.

September 17, 2020

Amwell®, a national telehealth leader, has announced the pricing of its upsized initial public offering of 41,222,222 shares of its Class A common stock at an initial public offering price of US$18.00 per share for total gross proceeds of approximately US$742 million, before deducting underwriting discounts and commissions and offering expenses payable by Amwell. In addition, the underwriters have been granted a 30-day option to purchase up to 6,183,333 additional shares of Class A common stock at the initial public offering price, less underwriting discounts and commissions, from Amwell and certain stockholders of Amwell (the “Selling Stockholders”). Amwell will not receive any proceeds from the sale of Class A common stock by the Selling Stockholders.

Latham & Watkins LLP represents the underwriters in the offering with a capital markets team led by New York partners Michael Benjamin and Nathan Ajiashvili, with New York associates Salvatore Vanchieri, Matthew DeSilva and Ian Lachow.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.